Peer-reviewed veterinary case report
How blood tests help find heart disease in Dobermanns
By Dukes-McEwan, J et al.·Published in The Journal of small animal practice·2022·Department of Small Animal Clinical Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Usefulness of cardiac biomarker screening to detect dilated cardiomyopathy in Dobermanns.
- Species:
- dog
Plain-English summary
A group of Dobermanns underwent cardiac testing to check for dilated cardiomyopathy, a serious heart condition. The tests included measuring specific heart proteins (N-terminal pro-BNP and Troponin I) and using echocardiography and Holter monitoring to assess their heart health. The results showed that about 42% of the dogs had dilated cardiomyopathy, and the biomarkers were effective in identifying those at risk. This screening can help veterinarians decide which dogs need more detailed heart examinations, potentially leading to earlier treatment and better outcomes for affected pets.
People also search for: Doberman heart disease symptoms · dilated cardiomyopathy in dogs · heart test for Dobermans
Abstract
OBJECTIVES: To assess the diagnostic accuracy of two cardiac biomarker assays (N-terminal pro-BNP , Troponin I) in detecting dilated cardiomyopathy in Dobermanns. MATERIALS AND METHODS: Dobermanns undergoing cardiac biomarker testing were screened by echocardiography and Holter monitoring, then assigned to a group: normal, equivocal, arrhythmia form of dilated cardiomyopathy, echocardiographic form of dilated cardiomyopathy or both. Some were reassessed to identify final status. Initial cardiac biomarker results were compared to final status. Receiver operating characteristic curves were used to identify area under the curve and corresponding sensitivity (Se), specificity (Sp) for different cut-offs (CO) for each cardiac biomarker. RESULTS: A total of 118 Dobermanns with cardiac biomarker data had echocardiography/Holter assessment. Repeat assessment was carried out in 47 Dobermanns after 394.5 ±151.0 days. Seventeen dogs changed group between initial and final status. The final status of 59 was normal, nine were equivocal and 50 had dilated cardiomyopathy (prevalence 42.4%). Of the dilated cardiomyopathy group, 25 had dilated cardiomyopathy-both, 13 dilated cardiomyopathy-echocardiography and 12 dilated cardiomyopathy-Holter. Receiver operating characteristic area under the curve=0.807 for N-terminal proBNP (Se 0.69 and Sp 0.81) and 0.873 for high-sensitivity cardiac Troponin I (Se 0.77 and Sp 0.86). When both Se and Sp were optimised for all forms of dilated cardiomyopathy, N-terminal proBNP cut-off was 626 pmol/L (Se and Sp 0.79) and high-sensitivity cardiac Troponin I cut-off was 0.056 ng/mL (Se and Sp 0.84). Receiver operating characteristic area under the curve was higher for dilated cardiomyopathy-echocardiography (NT-proBNP 0.883; high-sensitivity cardiac Troponin I 0.907) than dilated cardiomyopathy-Holter. CLINICAL SIGNIFICANCE: Cardiac biomarker screening may be useful to select Dobermanns which would benefit from further assessment by echocardiography and Holter.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34897698/